PIK3CA and non-small cell lung carcinoma: Finally, TP53 co-mutations were reported in 51.7%, CDKN2A/B in 17.2–27.2%, PIK3CA in 5% and CTNNB1 in 4.4% of ERBB2-mutant NSCLC [25], but these data are not comparable to our results due to the very small number of tumors with ERBB2 mutations included in our cohort.